About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, July 11th, 2017

The QualityStocks
Daily Stock List


iCo Therapeutics, Inc. (ICOTF)

OTC Markets Group, TheMicrocapNews, Wall St Report, and Vantage Wire reported previously on iCo Therapeutics, Inc. (ICOTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, iCo Therapeutics, Inc. identifies existing development stage assets for use in underserved ocular and infectious diseases. The Vancouver, British Columbia based Company owns the global exclusive rights to an oral delivery system -  Amphotericin B (Amp B) - for life-threatening infections. Amphotericin B is the gold standard for systemic antifungal drugs. It is one example of a well-established, highly efficacious systemic antifungal drug, which has a 50-year history of intravenous therapy.

ICo Therapeutics’ centers its efforts on development instead of research. The Company’s business model aims to acquire the rights to drugs that are either off-patent, presently approved or near commercialization, and develop them through redosing or reformulating them for new or expanded labels.

The above-mentioned existing development stage assets that the Company identifies may exhibit utility in non-ophthalmic conditions outside iCo Therapeutics’ core focus areas. If so, the Company will look to capture further value through partnerships, such as its partnership with Immune Pharmaceuticals (IMNP), which is in a number of Phase 2 studies involving iCo-008.

iCo-008 is also known as Bertilimumab or CAT-213. It is a human monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that acts as a messenger between the cells of the immune system. Immune Pharmaceuticals has initiated a Phase 2, double-blind, placebo controlled study with iCo-008 in 90 patients with moderate-to-severe ulcerative colitis.

iCo Therapeutics continued to advance its Oral Amphotericin B Delivery System (Oral Amp B) in 2016, undertaking pre-clinical pharmacokinetic and distribution studies employing its optimized formulations. The Company stated that data from these studies support the further development of its Oral Amp B with once a day dosing possible in certain indications.

In addition, iCo Therapeutics acquired in 2016 an exclusive option to in-license the global development and commercialization rights to a novel glaucoma asset. Moreover, the Company agreed that if it exercises the option it will out-license EU commercialization rights back to its Spanish partner in return for economic consideration.

Furthermore, in 2016, iCo’s Israeli partner continued to progress iCo-008 in two Phase 2 clinical studies: ulcerative colitis, an inflammatory bowel condition; and bullous pemphigoid, a dermatological condition.

iCo Therapeutics, Inc. (ICOTF), closed Tuesday's trading session at $0.0398, up 28.80%, on 200,000 volume with 16 trades. The average volume for the last 60 days is 7,290 and the stock's 52-week low/high is $0.024/$0.0666.

AltiGen Communications, Inc. (ATGN)

Marketbeat reported recently on AltiGen Communications, Inc. (ATGN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AltiGen Communications, Inc. is a provider of Hosted Skype for Business and Contact Center solutions. The Company is a foremost Microsoft Cloud Solutions provider. It delivers fully managed Unified Communications services, combining Hosted Skype for Business, Advanced Cloud PBX, and Innovative Cloud Contact Center applications with seamless integration to Office 365. AltiGen Communications is based in San Jose, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The design of AltiGen Communications’ solutions is for high reliability, ease of use, and seamless integration to Microsoft infrastructure technologies. The Company’s solutions are constructed on a scalable, open standards platform.

AltiGen’s inventive and feature rich Cloud PBX and Multi-Channel Contact Center solutions natively integrate with Skype for Business and Office 365. This is to deliver business-critical functionalities required by SMBs (Small and Midsize Businesses) and enterprises. AltiGen’s Cloud Unified Communications solution considerably simplifies deployment and management while enabling SMBs and enterprises to significantly decrease costs and lower total cost of ownership.  Furthermore, its all-software solution provides businesses the flexibility to deploy on-premises, in the Cloud, or in a hybrid environment.

The Company has its MaxACD Cloud. MaxACD enhances Skype for Business and Office 365 with Cloud-based Automated Multimedia Routing and Queuing capabilities to address the Enterprise “Line of Business” requirements for Internal or External customer requests.

AltiGen also has its Enterprise Cloud PBX. This is a comprehensive Cloud-based enterprise-wide PBX and Contact Center solution for Office 365, founded on the Company’s Hosted Skype for Business, integrated with its MaxACD advanced communications application set.

Furthermore, AltiGen’s MaxUC is a unique new Unified Communications solution. It combines the Company’s MaxCS IP PBX with Microsoft’s Skype for Business. AltiGen Communications also has its MaxCS SIP Trunk. Its SIP Trunk Service is an enterprise grade VoIP service optimized for AltiGen Communications solutions. 

Last month, AltiGen Communications announced that its Hosted Skype for Business solution has been successfully deployed by Capture Technologies. In addition to internally deploying the AltiGen Hosted Skype for Business solution for its own operations, Capture Technologies is reselling the solution to their own client base as part of the AltiGen Partner Program.

Capture Technologies is a technology solutions provider based in Oakland, California. The design of AltiGen Communication's Hosted Skype for Business solution is to take advantage of and enhance an enterprise’s deployment of Office 365.

AltiGen Communications will announce its Q3 fiscal year 2017 financial results after the close of regular market trading on Wednesday, July 26, 2017. In addition, the Company will hold a conference call to discuss the results at 2:00 p.m. Pacific Time (5:00 p.m. ET).

AltiGen Communications, Inc. (ATGN), closed Tuesday's trading session at $0.25, up 13.64%, on 200 volume with 1 trade. The average volume for the last 60 days is 5,266 and the stock's 52-week low/high is $0.1237/$0.28.

EXOlifestyle, Inc. (EXOL)

The Observer and Promotion Stock Secrets reported on EXOlifestyle, Inc. (EXOL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

EXOlifestyle, Inc. is a management organization that develops and operates unique and healthy brands within the health & wellness industry. The OTCQB-listed Company has a strong focus on athletic gear and apparel. Development of EXO was by experienced Crossfit Athletes who were looking for better training products, specifically knee sleeves.

EXOlifestyle’s main emphasis is on its EXO, Inc. subsidiary. This subsidiary is a designer and producer of active wear brands offered in national fitness retailers in the U.S. EXOlifestyle has its corporate office in Boca Raton, Florida.

In addition, the Company is the creator, present advisor, and strategist of the international, all-natural and organic pizza franchise, Pizza Fusion. ExoLifestyle leadership oversees the franchise's locations across the U.S. and Saudi Arabia.

Pizza Fusion specializes in organic fare free of artificial additives such as preservatives, growth hormones, pesticides, nitrates, and trans fats. The Pizza Fusion brand provides health conscious alternatives. It provides its customers with a 75 percent organic menu.

EXOlifestyle’s mission is to provide a quality, functional, and stylish knee sleeve that will stand up to its athletes’ training and competition protocol, every day. The Company’s intention is that its carefully manufactured products will enhance sport performance and muscle recovery for every athlete who puts on an Exo Sleeve.

Exo Sleeves contain anti-microbial material. This considerably lessens the ability of microorganisms to grow on the surface of the material. Consequently, this creates a longer use for the athlete, and a healthier way to train. Features of Exo Sleeves include pull on support and relief from arthritis, bursitis and tendonitis; specialized flat stitch technology that provides a flatter, cleaner and stronger seam; and seamless back-of-knee and anatomical design for added comfort.

Features also include latex-free neoprene, which provides thermal/compression therapy. Moreover, Exo Sleeves regulate body temperature; the outer heavy-duty nylon fabric is for durability; and the design is to enhance sport performance and muscle recovery. EXOlifestyle products also include knee wraps, wrist wraps, and weight belts targeted to the high-performance athletic market.

EXOlifestyle’s plans include expanding the fits, styles, and colors of its current offerings, and also expanding its offerings to numerous price points. It has customers in Canada, Mexico, the UK, UAE, New Zealand, and Australia. It expects to expand its efforts in these nations in Q3 2017, along with Spain, France, Italy, and Germany.

This past April, EXOlifestyle announced that its subsidiary, Pizza Fusion, announced it would be opening its newest franchised restaurant in Norfolk, Virginia in Old Dominion University's "University Village". The new restaurant marks the brand's first location with Aramark Food and Support Services Group, Inc. (ARMK). Aramark is in the customer service business and its affiliates include Aramark Corporation, Aramark Educational Services, Aramark Healthcare Support Services, and Aramark Sports and Entertainment Services.

EXOlifestyle, Inc. (EXOL), closed Tuesday's trading session at $0.0029, up 16.00%, on 56,000 volume with 2 trades. The average volume for the last 60 days is 4,007,453 and the stock's 52-week low/high is $0.0022/$0.23.

ImmuDyne, Inc. (IMMD)

PennyStocks24, Buzz Stocks, Planet Penny Stocks, Penny Pick Finders, SecretStockPromo, PennyStockProphet, and StockOnion reported previously on ImmuDyne, Inc. (IMMD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

ImmuDyne, Inc. is a health, wellness, and skincare company commercializing a portfolio of proprietary topical and orally delivered products. These rely on ImmuDyne’s patented and pure Yeast Beta Glucan ingredients. The Company has developed proprietary topical and oral products and a proprietary natural delivery technology with many new market opportunities.

In addition, ImmuDyne manufactures and sells yeast beta-1,3/1,6 glucan for oral and topical uses. The Company’s business strategy is to create new market spaces within the wellness industry via the launch of clinically researched, doctor recommended immune support products and services.  ImmuDyne has offices in Mt. Kisco, New York; Huntington Beach, California; San Juan, Puerto Rico; and Florence, Kentucky.

Through a highly complex, proprietary process that utilizes best-in-class technology, ImmuDyne can extract highly purified beta-1,3/1,6-D-glucan from the cell walls of Saccaharomyces cerevisiae. The Company says that it is well-established in the scientific community that beta-glucans are strong activators of the innate immune response. Recent studies indicate that yeast beta-1,3/1,6-D-glucans can also activate adaptive immune responses. The Company’s InateMD product line contains an ultra-pure Yeast Beta Glucan compound proven to support the human immune system.

Immudyne PR is a majority-owned subsidiary of ImmuDyne, Inc. Immudyne PR is the digital marketing arm of Immudyne and is now concentrating on marketing products for thicker and fuller hair (Shapiro MD) and a skincare line containing Immudyne’s proprietary Yeast Beta Glucan ingredient (Inate MD).

ImmuDyne’s corporate vision is to establish a global communications platform, which will educate consumers about the importance of immune health and the clinically proven health benefits of PURACERE™ and NAYAD®. PURACERE™ is a patent protected and clinically researched dietary supplement. It is the purist yeast beta-1,3/1,6-D-glucan available.

Last month, ImmuDyne announced the successful national launch of its patented Shapiro MD product line. Within the first several weeks of the product’s launch on Facebook, the Company sold all available inventory. The Shapiro MD product line is the result of 15 years of research and development by dermatologists Dr. Steven Shapiro and Dr. Michael Borenstein.  It is protected by two United States patents.

Yesterday, ImmuDyne announced Immudyne PR has partnered with MH Caribbean Management, LLC (MHCM).  MHCM is the owner and operator of an Amazon Store ranked as an Amazon USA top 1000 seller (as per Marketplace Pulse).

Mr. Justin Schreiber, President of Immudyne PR, stated “The Amazon selling platform has become essential for brands large and small seeking to reach the global consumer. This partnership provides immediate and lasting benefits for Shapiro MD and future products launched by Immudyne PR.” 

ImmuDyne, Inc. (IMMD), closed Tuesday's trading session at $0.4554, up 33.94%, on 127,743 volume with 39 trades. The average volume for the last 60 days is 51,581 and the stock's 52-week low/high is $0.1999/$0.95.

SpendSmart Networks, Inc. (SSPC)

Marketbeat and Flagler Financial Group reported earlier on SpendSmart Networks, Inc. (SSPC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

SpendSmart Networks, Inc. does business as SMS Masterminds (SMS). The Company provides proprietary loyalty systems and a collection of digital engagement and marketing services. These help local merchants build relationships with consumers and build revenues. SpendSmart’s plan is to expand on its existing markets and seek new markets with strong product and service offerings. The Company previously went by the name The SpendSmart Payments Company, Inc. It changed its corporate name to SpendSmart Networks, Inc. in June of 2014. SpendSmart Networks has its head office in San Luis Obispo, California.

SpendSmart Networks delivers and manages loyalty platforms. These include merchant funded rewards, loyalty rewards tablet/kiosk, and proprietary rewards management systems. Furthermore, it delivers and manages mobile marketing technology. This includes text and email messaging, customer analytics and propensity marketing, patent pending automated engagement engine, and Text2Win sweepstakes features.

SpendSmart Networks is a specialist in Mobile. The Company helps local businesses find new customers, and turn existing customers into digital advocates. SpendSmart will optimize a client’s website, produce more reviews, and also get a client’s customers to return more frequently through SpendSmart’s loyalty and text message marketing strategies.

The Company also delivers and manages enterprise level loyalty and mobile marketing consulting. This comprises monthly hands on reviews by its Certified Masterminds, campaign creation and optimization, as well as localized support. In addition, SpendSmart provides mobile and loyalty marketing services for small and medium sized businesses. It also provides personalized Website, e-commerce, and mobile application (app) development services; and Web marketing tools and analytics.

SpendSmart Networks is focusing on the increasing mobile advertising market. Its services are implemented and supported by a broad network of certified digital marketing specialists (Certified Masterminds) who increase revenue and consumer relationships for merchants by way of loyalty programs, mobile marketing, and website development.

Consumers' dollars go further when they spend it with merchants in the SpendSmart network of merchants. This is because they receive exclusive deals, earn rewards, and in due course build a connection with their favorite merchants.

In September of 2016, SMS Masterminds announced the return of its United States Veteran's recruitment initiative named "Heroes Among Us." SMS Masterminds unveiled its first Veteran's program providing financial discounts and incentives to current and discharged Veterans, in 2013. The renewed program offered financial incentives of up to $7,000 to qualified Veterans looking to become a certified Mastermind in an exclusive territory. Participation in the program was limited to ten accepted applicants recruited through different search initiatives. Hallmarks of this program are performance-based rewards, which help offset the initial investment of $28,800 paid by new licensees at the start of their initial contract.

SpendSmart Networks, Inc. (SSPC), closed Tuesday's trading session at $0.015, up 15.38%, on 9,333 volume with 2 trades. The average volume for the last 60 days is 58,503 and the stock's 52-week low/high is $0.0082/$0.12.


The QualityStocks
Company Corner


ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.60, up 30.43%, on 166,095 volume with 66 trades. The stock’s average daily volume over the past 60 days is 57,413 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. today announces its agreement with a national deployment partner to manage the deployment, implementation and scaling of the ORHub Surgical Resource Management Platform in hospitals that serve 10 major U.S. metropolitan markets. Specialized in launching and supporting health care solutions nationwide, the deployment partner gives ORHub access to valuable health care-focused resources, enabling the Company to quickly roll-out its transformative medical software and facilitate continued corporate growth.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Signs National Deployment Agreement to Roll-out Transformative Medical Software in Major U.S. Markets

Microsoft Publication Demonstrates Vital Capabilities of ORHub, Inc.'s Surgical Resource Management Solution

ORHub, Inc. Continues Market Expansion with New Customer-Requested Specialty Modules

Converde Energy USA, Inc. (XFUL)

The QualityStocks Daily Newsletter would like to spotlight Converde Energy USA, Inc. (XFUL). Today, Converde Energy USA, Inc. closed trading at $0.00375, up 20.97%, on 175,500 volume with 13 trades. The stock’s average daily volume over the past 60 days is 1,563,025, and its 52-week low/high is $0.0002/$0.10.

Converde Energy USA, Inc. (XFUL), d/b/a American Energy Partners Inc., and its group of companies are dedicated to delivering solutions wherever energy production and water meet technology. The company has positioned itself to benefit from above-favorable margins on each of its subsidiaries due to the synergy of the chain of revenues.

Hydration Company of PA (HCPA)
Hydration Company of PA focuses on sourcing, implementing and distributing reclaimed water at a profit. This subsidiary's competitive advantage mainly lies within its pure volume of reclaimed water and its access to low cost treatment with high flow rates and highly concentrated solids through the technologies of XFUL's partners. Because of the volume as well as the flexibility of the model established via patent pending methodology and conveyance methods, HCPA can effectively gain market share immediately as large corporations prefer access to one source that can supply massive amounts of reclaimed water regardless of drought conditions.

American Energy Solutions, LLC
American Energy Solutions, LLC utilizes a network of partners to provide off-the-shelf and custom-designed treatment technologies that contribute to HCPA's business model of low-cost treatment and distribution. As a provider of design, this subsidiary is capable of repeatable and synergistic services across the value chain. American Energy's long-term plan is to utilize an in-house team to grow market share as water use continues to become more critical to modern industry.

Gilbert Oil & Gas Company
Gilbert Oil & Gas Company is leveraging broad industry valuation experience to move forward on its mission to add shareholder value through drilling, operating, and partnership opportunities in the upstream oil and gas space. Equipped with the in-house capabilities necessary to source and evaluate opportunities for profitability, Gilbert is positioned to become a strong customer of XFUL's other subsidiaries, providing them with the foundation to attract other customers and enter new markets.

Integrated Business Strategy
By combining ownership of water sources via Hydration Company of PA, design and treatment solutions via American Energy Solutions, and a stream of promising opportunities via Gilbert Oil & Gas Company, XFUL is essentially creating a positive revenue feedback loop. This synergistic business model also opens opportunity for higher profit margins, additional revenue, and faster growth in new markets. Disclaimer

Converde Energy USA, Inc. Company Blog

Converde Energy USA, Inc. News:

Converde Energy USA, Inc. Appoints Josh Hickman, President of Subsidiary's O&G Operations and to Board of Directors

American Energy Partners, Inc. (XFUL) d/b/a Converde Energy USA, Inc. Engages NetworkNewsWire for Corporate Communications Solutions

Converde Energy USA, Inc. to Receive up to $3M Investment from GPL Ventures, LLC

Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.013, up 1.09%, on 62,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 81,701, and its 52-week low/high is $0.0061/$0.10.

Epazz, Inc. (EPAZ), is an enterprise-wide software company specializing in customized web applications for higher education institutions and the public sector. Through its proprietary BoxesOS applications, the company aims to create and maintain virtual communities that facilitate enhanced communication and provide up-to-date information and content in order to streamline the decision-making process for its clients. Epazz's BoxesOS also serves as a secure digital marketplace for various types of commerce, allowing the company to meet the increasing information technology demands of the 21st century.

In addition to its BoxesOS administrative services, Epazz offers a full end-user suite of solutions designed to maximize communication and functionality with full-featured web-based intranet software. Leveraging these offerings, the company's clients gain secure access and administrative control to customized features based on their unique needs. For businesses, the value of implementing these services can be tremendous. According to data from the McKinsey Global Institute, productivity improves by as much as 25 percent in organizations with connected employees. Studying just four commercial sectors (consumer packaged goods, retail financial services, advanced manufacturing and professional services), McKinsey estimates that the fiscal contributions of implementing effective intranet solutions could amount to as much as $1.3 trillion annually.

BoxesOS also allows companies to enhance communications with stakeholders by providing one-stop access to elegant, web-enabled information dashboards designed for specific user groups. Offering the ability to create unique dashboards for each stakeholder group addresses one of the most prominent issues facing workplace intranet projects – lack of engagement. Industry data suggest that properly engaging three core types of stakeholders, including executives, implementers and users, as well as the many sub-types within each of those groups, is key to the successful implementation of digital workplace solutions.

Outside of its business software solutions, Epazz is currently addressing a rising demand in the legal cannabis industry through its ZenaPay payment system. While banks remain hesitant regarding the legality of state-approved cannabis programs, dispensaries and related businesses have been compelled to operate on a cash-only basis, creating both security concerns and inconvenience for their customers. With ZenaPay, Epazz seeks to eliminate this issue by relying on the widely-used bitcoin cryptocurrency to provide an alternative to cash transactions. These efforts are particularly intriguing when studying the forward projections associated with marijuana sales. Per ArcView Market Research, North American marijuana sales grew by an unprecedented 30 percent in 2016 to $6.7 billion, and this figure is expected to top $20.2 billion by 2021.

Epazz is led by founder, chairman and CEO Shaun Passley, Ph.D. Founding the company in February 1999, Passley has been the guiding force behind Epazz's software and product development, as well as its continuing development of future products and services. Passley is joined on the Epazz management team by Raymond Kennedy, director of sales. Kennedy has more than two decades of experience in enterprise software sales, having previously served as marketing director for HCM, Inc., where he established six new sales territories and increased overall sales by more than 30 percent. Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Epazz, Inc. Featured on MoneyTV with Donald Baillargeon, 6/2

Epazz, Inc. Reports Increase First Quarter Revenue and Profitability; Company is Focusing on Improving Fundamentals; Increasing Sales, Reducing Operational Expenses and Increasing Income

Epazz, Inc. Launches Zenapay.com, the Company's New Cannabis Payment System

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.258, up 1.18%, on 182,140 volume with 125 trades. The stock’s average daily volume over the past 60 days is 551,358, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Signs R&D Agreement with ATERA

InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media

InMed Announces Agreement to Advance a Topical Formulation of INM-750

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.50, up 1.83%, on 104 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,231, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility Media Corp. Selects PCG Advisory Group for Investor Relations and Strategic Communications

ProBility Media Corp. Closes the Acquisition of W Marketing

ProBility Media Corp. Reports Fourth Consecutive Quarter of Revenue Growth


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(TEUM) +133.87%


(HK) +51.35%


(ARNA) +41.38%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251